Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of alisertib in relapsed or refractory urothelial carcinoma
2014-000557-36Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alisertib in transitional cell carcinoma (TCC), bladder cancer, upper tract urothelial carcinoma (UTUC) and 1 more, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoints: Response rate and Progression-free survival. Started Mar 2014; status: completed.
02
Drugs
alisertib
03
Conditions
transitional cell carcinoma (TCC)bladder cancerupper tract urothelial carcinoma (UTUC)urethral urothelial carcinoma
Beyond the preview
Go deeper on 2014-000557-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000557-36.